SLEEP-CYCLE
2.12.2020 10:34:52 CET | Business Wire | Press release
Sleep Cycle , the world’s most popular intelligent alarm clock app that analyzes users’ sleep, today announces its first partnership with one of the world’s leading meditation apps, Petit BamBou to provide its global users with relaxation content for better sleep during these uncertain times.
Sleep Cycle will be hosting meditation content by Petit BamBou in their Sleep Aid program, which features a series of audio productions designed to aid in falling asleep. The content offers users an improved bedtime routine to help them relax and unwind before going to sleep for a better night’s rest.
“Sleep is as much about physical health as it is about the well-being of the mind. Implementing a sleep routine that works in meditation can help prepare for a more restful sleep,” said Andreas Roman, head of content at Sleep Cycle. “By adding Petit BamBou’s meditation tracks to our carefully curated content library, we’re helping users find a place for meditation in their lives to reach a new level of relaxation.”
Starting today, Sleep Cycle will be releasing four meditation tracks to its Sleep Aid library throughout Dec. 1–11 for premium users. Freemium users will have access to the first meditation track from Dec. 1–14.
“Recent world events showed us how critical sleep is for our well-being,” said Benjamin Blasco, co-founder of Petit BamBou. “Mindfulness meditation has become a fast-growing topic for clinical studies on sleep. It involves focusing on your breathing and then bringing your mind’s attention to the present without drifting into concerns about the past or future. It helps break the train of everyday thoughts to evoke the relaxation response, creating a reflex to more easily bring forth a sense of relaxation.”
Whether you’re a beginner or a lifelong practitioner, using a guided meditation program can help fall you asleep more easily, sleep better and wake up more rested and restored. To learn more about how meditation can improve sleep health, please read Sleep Cycle’s editorial article, “The Benefits of Meditation for Sleep.”
About Sleep Cycle
Sleep Cycle is the world’s most popular intelligent alarm clock app that analyzes users’ sleep, records findings and wakes them during their lightest sleep phase so they feel rested and refreshed. The app generates nightly sleep reports, tracks long-term sleep trends, and logs how daily activities impact sleep quality. With millions of users worldwide, Sleep Cycle has become the world’s richest repository of data on global sleep habits.
About Petit BamBou
Petit BamBou is the leading mindfulness and mental health European mobile app with 6.5 million users. The freemium app proposes 8 sessions for free and offers one of the largest catalog (900+ sessions on various themes : work, kids, sleep, burnout, couple, anxiety, smoking) from the best experts. The users love Petit BamBou for its combination of humour and wisdom, and the sessions blending cartoons and guided audio. The app is available in 6 languages (English, French, German, Spanish, Italian, and soon Dutch).
A Sleep Cycle Production:
Download Sleep Cycle for iOS
Download Sleep Cycle for Android
Visit SleepCycle.com
Download press images
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom